EZCORPの空売り状況は、投資家がEZCORPの株価下落に賭けている度合いを知ることができます。空売りデータは2週間ごとに更新されます。

EZCORP (NASDAQ:EZPW) 株価情報, 空売り情報

EZCORP

EZCORP Inc is a United States-based company engaged in offering pawn loans in the United States and Mexico. It also offers short-term unsecured loans and other consumer financial products, and buy and sell second-hand goods. The operating segments of the company are us Pawn, Latin America Pawn, and other international. us Pawn segment includes all pawn activities in the United States. Latin America Pawn segment includes all pawn activities in Mexico and other parts of Latin America. The company generates revenue from merchandise sales, jewelry scrapping sales, and pawn service charges, of which key revenue is derived from the merchandise sales which are primarily collateral forfeited from pawn lending operations and used merchandise purchased from the customers.

EZCORP, Inc. - Class A Non-Voting Common Stock

EZCORP Inc

Here are three stocks with buy rank and strong value characteristics for investors to consider today, February 11th:
OMV Aktiengesellschaft OMVKY: This energy and chemicals company carries a Zacks Rank #1, and has witnessed the Zacks Consensus Estimate for its current year earnings increasing 4.5% over the last 60 days.
<div class="chart_embed">
<h3>OMV AG Price and Consensus</h3>
<a href="https://www.zacks.com/stock/chart/OMVKY/price-consensus-chart?icid=chart-OMVKY-price-consensus-chart"><img alt="OMV AG Price and Consensus" src="https://staticx-tuner.zacks.com/images/charts/f0/1739262717.png" style="height:264px; width:527px" title="" /> </a>
<a href="https://www.zacks.com/stock/chart/OMVKY/price-consensus-chart?icid=chart-OMVKY-price-consensus-chart">OMV AG price-consensus-chart</a> | <a href="https://www.zacks.com/stock/quote/OMVKY?icid=chart-OMVKY-price-consensus-chart">OMV AG Quote</a>
</div>
OMV has a price-to-earnings ratio (P/E) of 5.96, compared with 7.30 for the industry. The company possesses a <a href="https://www.zacks.com/style-scores-education/">Value Score</a>&nbsp; of A.
<div class="chart_embed">
<h3>OMV AG PE Ratio (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/ttm#NYSE">TTM</a>)</h3>
<a href="https://www.zacks.com/stock/chart/OMVKY/fundamental/pe-ratio-ttm?icid=chart-OMVKY-fundamental/pe-ratio-ttm">TTM</a>)&quot; height=&quot;250&quot; src=&quot;https://staticx-tuner.zacks.com/images/charts/c9/1739262943.png&quot; title=&quot;&quot; width=&quot;493&quot; /&gt;
<a href="https://www.zacks.com/stock/chart/OMVKY/fundamental/pe-ratio-ttm?icid=chart-OMVKY-fundamental/pe-ratio-ttm">OMV AG pe-ratio-ttm</a> | <a href="https://www.zacks.com/stock/quote/OMVKY?icid=chart-OMVKY-fundamental/pe-ratio-ttm">OMV AG Quote</a>
</div>
Pacira BioSciences, Inc. PCRX: This non-opioid pain management and regenerative health solutions company carries a Zacks Rank #1, and has witnessed the Zacks Consensus Estimate for its next year earnings increasing 21% over the last 60 days.
<div class="chart_embed">
<h3>Pacira BioSciences, Inc. Price and Consensus</h3>
<a href="https://www.zacks.com/stock/chart/PCRX/price-consensus-chart?icid=chart-PCRX-price-consensus-chart"><img alt="Pacira BioSciences, Inc. Price and Consensus" src="https://staticx-tuner.zacks.com/images/charts/18/1739262729.png" style="height:264px; width:568px" title="" /> </a>
<a href="https://www.zacks.com/stock/chart/PCRX/price-consensus-chart?icid=chart-PCRX-price-consensus-chart">Pacira BioSciences, Inc. price-consensus-chart</a> | <a href="https://www.zacks.com/stock/quote/PCRX?icid=chart-PCRX-price-consensus-chart">Pacira BioSciences, Inc. Quote</a>
</div>
Pacira has a price-to-earnings ratio (P/E) of 7.69, compared with 24.45 for the S&amp;P 500. The company possesses a Value Score of A.
<div class="chart_embed">
<h3>Pacira BioSciences, Inc. PE Ratio (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/ttm#NYSE">TTM</a>)</h3>
<a href="https://www.zacks.com/stock/chart/PCRX/fundamental/pe-ratio-ttm?icid=chart-PCRX-fundamental/pe-ratio-ttm">TTM</a>)&quot; height=&quot;250&quot; src=&quot;https://staticx-tuner.zacks.com/images/charts/35/1739262962.png&quot; title=&quot;&quot; width=&quot;527&quot; /&gt;
<a href="https://www.zacks.com/stock/chart/PCRX/fundamental/pe-ratio-ttm?icid=chart-PCRX-fundamental/pe-ratio-ttm">Pacira BioSciences, Inc. pe-ratio-ttm</a> | <a href="https://www.zacks.com/stock/quote/PCRX?icid=chart-PCRX-fundamental/pe-ratio-ttm">Pacira BioSciences, Inc. Quote</a>
</div>
EZCORP, Inc. EZPW: This pawn services company carries a Zacks Rank #1, and has witnessed the Zacks Consensus Estimate for its current year earnings increasing 3.2% over the last 60 days.
<div class="chart_embed">
<h3>EZCORP, Inc. Price and Consensus</h3>
<a href="https://www.zacks.com/stock/chart/EZPW/price-consensus-chart?icid=chart-EZPW-price-consensus-chart"><img alt="EZCORP, Inc. Price and Consensus" src="https://staticx-tuner.zacks.com/images/charts/f4/1739262742.png" style="height:264px; width:568px" title="" /> </a>
<a href="https://www.zacks.com/stock/chart/EZPW/price-consensus-chart?icid=chart-EZPW-price-consensus-chart">EZCORP, Inc. price-consensus-chart</a> | <a href="https://www.zacks.com/stock/quote/EZPW?icid=chart-EZPW-price-consensus-chart">EZCORP, Inc. Quote</a>
</div>
Ezcorp has a price-to-earnings ratio (P/E) of 10.33, compared with 15.30 for the industry. The company possesses a Value Score of A.
<div class="chart_embed">
<h3>EZCORP, Inc. PE Ratio (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/ttm#NYSE">TTM</a>)</h3>
<a href="https://www.zacks.com/stock/chart/EZPW/fundamental/pe-ratio-ttm?icid=chart-EZPW-fundamental/pe-ratio-ttm">TTM</a>)&quot; height=&quot;251&quot; src=&quot;https://staticx-tuner.zacks.com/images/charts/b8/1739262981.png&quot; title=&quot;&quot; width=&quot;532&quot; /&gt;
<a href="https://www.zacks.com/stock/chart/EZPW/fundamental/pe-ratio-ttm?icid=chart-EZPW-fundamental/pe-ratio-ttm">EZCORP, Inc. pe-ratio-ttm</a> | <a href="https://www.zacks.com/stock/quote/EZPW?icid=chart-EZPW-fundamental/pe-ratio-ttm">EZCORP, Inc. Quote</a>
</div>
&nbsp;
See <a href="https://www.zacks.com/stocks/buy-list/?ADID=zp_1link&amp;ICID=zpi%20_1link">the full list of top ranked stocks here.</a>
&nbsp;
Learn more about the <a href="https://www.zacks.com/education/stock-scorecard/value-trading">Value score and how it is calculated here.</a>
&nbsp;
<h2>Only $1 to See All Zacks&#39; Buys and Sells</h2>
We&#39;re not kidding.
Several years ago, we shocked our members by offering them 30-day access to all our picks for the total sum of only $1. No obligation to spend another cent.
Thousands have taken advantage of this opportunity. Thousands did not - they thought there must be a catch. Yes, we do have a reason. We want you to get acquainted with our portfolio services like&nbsp;Surprise Trader, Stocks Under $10, Technology Innovators,and more, that closed 256 positions with double- and triple-digit gains in 2024 alone.
<a href="https://www.zacks.com/registration/ultimatetrader/welcome/eoffer/6328?adid=SYND_BENZ_ZU_ZU_ZACKS1RANKADDITIONS_268_02112025_2413286&amp;cid=CS-BENZ-FT-zacks_1_rank_additions|value_additions-2413286" style="font-weight:bold">See Stocks Now &gt;&gt;</a>
&nbsp;
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. <a href="https://www.zacks.com/registration/pfp/?ALERT=RPT_7BST_LP194&amp;ADID=SYND_BENZ_7BEST_ZACKS1RANKADDITIONS_268_2413286&amp;cid=CS-BENZ-FT-zacks_1_rank_additions|value_additions-2413286" target="_blank">Click to get this free report</a>

&nbsp; 
<a href="https://www.zacks.com/registration/pfp?ALERT=ZER_LINK&amp;t=EZPW&amp;ADID=SYND_BENZ_TCK_ZACKS1RANKADDITIONS_268_2413286_EZPW&amp;cid=CS-BENZ-FT-zacks_1_rank_additions|value_additions-2413286">EZCORP, Inc. (NASDAQ: </a><a class="ticker" href="https://www.benzinga.com/stock/ezpw#NASDAQ">EZPW</a>): Free Stock Analysis Report 
&nbsp; 
<a href="https://www.zacks.com/registration/pfp?ALERT=ZER_LINK&amp;t=PCRX&amp;ADID=SYND_BENZ_TCK_ZACKS1RANKADDITIONS_268_2413286_PCRX&amp;cid=CS-BENZ-FT-zacks_1_rank_additions|value_additions-2413286">Pacira BioSciences, Inc. (NASDAQ: </a><a class="ticker" href="https://www.benzinga.com/stock/pcrx#NASDAQ">PCRX</a>): Free Stock Analysis Report 
&nbsp; 
<a href="https://www.zacks.com/registration/pfp?ALERT=ZER_LINK&amp;t=OMVKY&amp;ADID=SYND_BENZ_TCK_ZACKS1RANKADDITIONS_268_2413286_OMVKY&amp;cid=CS-BENZ-FT-zacks_1_rank_additions|value_additions-2413286">OMV AG (OMVKY): Free Stock Analysis Report</a>
<a href="https://www.zacks.com/commentary/2413286/best-value-stocks-to-buy-for-february-11th?cid=CS-BENZ-FT-zacks_1_rank_additions|value_additions-2413286">To read this article on Zacks.com click here.</a>
<a href="https://www.zacks.com/">Zacks Investment Research</a>

Equities

Small Cap

Markets

EZPW

PCRX

Best Value Stocks To Buy For February 11th

Canaccord Genuity analyst Brian McNamara maintains EZCORP (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EZPW#NASDAQ">EZPW</a>) with a Buy and raises the price target from $19 to $22.

News

Price Target

Analyst Ratings

Canaccord Genuity Maintains Buy on EZCORP, Raises Price Target to $22

Stephens &amp; Co. analyst Kyle Joseph reiterates EZCORP (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EZPW#NASDAQ">EZPW</a>) with a Equal-Weight and maintains $13.5 price target.

Reiteration

Stephens & Co. Reiterates Equal-Weight on EZCORP, Maintains $13.5 Price Target

The earnings results for EZCORP (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EZPW#NASDAQ">EZPW</a>) for Q1 were made public on Wednesday, February 5, 2025 at 04:48 PM.
Here's a comprehensive overview of the announcement.
<h3>Earnings</h3>
EZCORP beat estimated earnings by 14.000000000000002%, reporting an EPS of $0.42 versus an estimate of $0.37.
Revenue was up $20.18 million from the same period last year.
<h3>Past Earnings Performance</h3>
The company missed on EPS by $0.0 in the last quarter, resulting in a 1.0% increase share price change the following day.
Here's a look at EZCORP's past performance:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.26</td>
<td>0.21</td>
<td>0.25</td>
<td>0.28</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.26</td>
<td>0.23</td>
<td>0.28</td>
<td>0.36</td>
</tr>
<tr>
<td>Revenue Estimate</td>
<td>288.49M</td>
<td>279.55M</td>
<td>282.19M</td>
<td>296.13M</td>
</tr>
<tr>
<td>Revenue Actual</td>
<td>294.55M</td>
<td>281.42M</td>
<td>285.64M</td>
<td>299.99M</td>
</tr>
</tbody>
</table>

To track all earnings releases for EZCORP <a href="https://www.benzinga.com/quote/EZPW/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings

EZCORP Q1 Earnings Report: What Investors Need to Know

EZCORP (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EZPW#NASDAQ">EZPW</a>) reported quarterly earnings of $0.42 per share which beat the analyst consensus estimate of $0.37 by 13.51 percent. This is a 16.67 percent increase over earnings of $0.36 per share from the same period last year. The company reported quarterly sales of $320.200 which missed the analyst consensus estimate of $322.828 million by 100.00 percent. This is a 100.00 percent decrease over sales of $299.991 million the same period last year.

Earnings Beats

Earnings Misses

EZCORP Q1 2025 Adj. EPS $0.42 Beats $0.37 Estimate, Sales $320.200 Miss $322.828M Estimate

ALGN

AMSC

AOSL

APPS

ARAY

ARCC

ARES

ASGN

ASYS

AZTA

BARK

BLBD

BSBR

CENT

CENTA

CMRE

CNMD

CNXN

COHR

CPAY

CPRI

CRTO

CSGS

CTSH

CTVA

DGII

DLHC

ENSG

EQNR

FORM

GEOS

HOLX

ITUB

KMPR

LFVN

LSAK

LUCK

LVWR

MSTR

MTRX

MUSA

NOTV

NTGR

NVST

NWSA

ODFL

ORLY

PAHC

PFGC

Earnings Scheduled For February 5, 2025

EZCORP (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EZPW#NASDAQ">EZPW</a>) reported quarterly earnings of $0.26 per share which missed the analyst consensus estimate of $0.27 by 3.7 percent. The company reported quarterly sales of $294.55 million which beat the analyst consensus estimate of $288.49 million by 2.10 percent. This is a 8.90 percent increase over sales of $270.48 million the same period last year.

EZCORP Q4 2024 Adj EPS $0.26 Misses $0.27 Estimate, Sales $294.55M Beat $288.49M Estimate

Stephens &amp; Co. analyst Kyle Joseph initiates coverage on EZCORP (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EZPW#NASDAQ">EZPW</a>) with a Equal-Weight rating and announces Price Target of $13.

Initiation

Stephens & Co. Initiates Coverage On EZCORP with Equal-Weight Rating, Announces Price Target of $13

ACXP

ADAP

AEMD

AFCG

AFYA

AGRO

AIRJ

ALUR

ALVO

ARCO

ATEX

AYTU

BCDA

BETR

BFRI

BITF

Bakkt Holdings, Inc. Class A Common Stock

BKKT

BNGO

BOXL

BRFS

BWEN

CAAS

CAPR

CREX

CRNT

CSAN

CSCO

CSLR

CSTE

CYBR

DADA

DMAC

DOLE

DRRX

DTCK

ECOR

EDBL

ENLT

FORA

FPAY

FULC

GILT

GLAD

GOEV

GRYP

HIVE

HROW

HYZN

IBTA

ICAD

ICCC

INLX

INVZ

JAGX

JJSF

KBDC

KLIC

KMDA

KRMD

KULR

LMFA

LOAR

LQDA

LUCD

LVLU

MCRB

MPTI

MRSN

NTWK

NXGL

OMER

OPRX

OTRK

OWLT

OXBR

PAVM

PCYO

Earnings Scheduled For November 13, 2024

EZCORP (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EZPW#NASDAQ">EZPW</a>) is preparing to release its quarterly earnings on Wednesday, 2024-11-13. Here's a brief overview of what investors should keep in mind before the announcement.
Analysts expect EZCORP to report an earnings per share (EPS) of $0.26.
The market awaits EZCORP's announcement, with hopes high for news of surpassing estimates and providing upbeat guidance for the next quarter.
It's important for new investors to understand that guidance can be a significant driver of stock prices.
<h3>Historical Earnings Performance</h3>
The company's EPS beat by $0.02 in the last quarter, leading to a 0.67% increase in the share price on the following day.
Here's a look at EZCORP's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.21</td>
<td>0.25</td>
<td>0.28</td>
<td>0.17</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.23</td>
<td>0.28</td>
<td>0.36</td>
<td>0.23</td>
</tr>
<tr>
<td>Price Change %</td>
<td>1.0%</td>
<td>-4.0%</td>
<td>12.0%</td>
<td>-3.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2024/1731427318_0.png" alt="eps graph" />
<h3>Market Performance of EZCORP's Stock</h3>
Shares of EZCORP were trading at $11.77 as of November 11. Over the last 52-week period, shares are up 37.05%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. 
<h3>Analyst Insights on EZCORP</h3>
For investors, staying informed about market sentiments and expectations in the industry is paramount. This analysis provides an exploration of the latest insights on EZCORP.
Analysts have provided EZCORP with 1 ratings, resulting in a consensus rating of Buy. The average one-year price target stands at $19.0, suggesting a potential 61.43% upside.
<h3>Peer Ratings Comparison</h3>
The below comparison of the analyst ratings and average 1-year price targets of and EZCORP, three prominent players in the industry, gives insights for their relative performance expectations and market positioning.
<h3>Insights: Peer Analysis</h3>
In the peer analysis summary, key metrics for and EZCORP are highlighted, providing an understanding of their respective standings within the industry and offering insights into their market positions and comparative performance.

<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>EZCORP</td>
<td>Buy</td>
<td>10.01%</td>
<td>$166.73M</td>
<td>2.24%</td>
</tr>
</tbody>
</table>

Key Takeaway:
EZCORP is positioned at the bottom for Revenue Growth among its peers. In terms of Gross Profit, EZCORP is also at the bottom compared to its peers. However, EZCORP is at the top for Return on Equity among its peers.
<h3>Delving into EZCORP's Background</h3>
EZCORP Inc is a United States-based company engaged in offering pawn loans in the United States and Mexico. It also offers short-term unsecured loans and other consumer financial products, and buy and sell second-hand goods. The operating segments of the company are us Pawn, Latin America Pawn, and other international. us Pawn segment includes all pawn activities in the United States. Latin America Pawn segment includes all pawn activities in Mexico and other parts of Latin America. The company generates revenue from merchandise sales, jewelry scrapping sales, and pawn service charges, of which key revenue is derived from the merchandise sales which are primarily collateral forfeited from pawn lending operations and used merchandise purchased from the customers.
<h3>A Deep Dive into EZCORP's Financials</h3>
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Revenue Growth: Over the 3 months period, EZCORP showcased positive performance, achieving a revenue growth rate of 10.01% as of 30 June, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Financials sector.
Net Margin: EZCORP's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 6.38%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): EZCORP's ROE excels beyond industry benchmarks, reaching 2.24%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): EZCORP's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 1.19% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: With a below-average debt-to-equity ratio of 0.76, EZCORP adopts a prudent financial strategy, indicating a balanced approach to debt management.
<a href="https://www.benzinga.com/quote/EZPW/earnings">To track all earnings releases for EZCORP visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings Preview For EZCORP

Canaccord Genuity analyst Brian McNamara maintains EZCORP (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EZPW#NASDAQ">EZPW</a>) with a Buy and maintains $19 price target.

Canaccord Genuity Maintains Buy on EZCORP, Maintains $19 Price Target

EZCORP To Acquire 53 Pawn Stores From Presta Dinero; Financial Terms Not Disclosed

While &quot;the trend is your friend&quot; when it comes to short-term investing or trading, timing entries into the trend is a key determinant of success. And increasing the odds of success by making sure the sustainability of a trend isn&#39;t easy.
Often, the direction of a stock&#39;s price movement reverses quickly after taking a position in it, making investors incur a short-term capital loss. So, it&#39;s important to ensure that there are enough factors -- such as sound fundamentals, positive earnings estimate revisions, etc. -- that could keep the momentum in the stock going.
Investors looking to make a profit from stocks that are currently on the move may find our &quot;Recent Price Strength&quot; screen pretty useful. This predefined screen comes handy in spotting stocks that are on an uptrend backed by strength in their fundamentals, and trading in the upper portion of their 52-week high-low range, which is usually an indicator of bullishness.
There are several stocks that passed through the screen:
<h2>Ezcorp</h2>
(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ezpw#NASDAQ">EZPW</a>) is one of them. Here are the key reasons why this stock is a solid choice for &quot;trend&quot; investing.
A solid price increase over a period of 12 weeks reflects investors&#39; continued willingness to pay more for the potential upside in a stock. EZPW is quite a good fit in this regard, gaining 16.7% over this period.
However, it&#39;s not enough to look at the price change for around three months, as it doesn&#39;t reflect any trend reversal that might have happened in a shorter time frame. It&#39;s important for a potential winner to maintain the price trend. A price increase of 4.7% over the past four weeks ensures that the trend is still in place for the stock of this consumer financial services company.
Moreover, EZPW is currently trading at 92.1% of its 52-week High-Low Range, hinting that it can be on the verge of a breakout.
Looking at the fundamentals, the stock currently carries a Zacks Rank #2 (Buy), which means it is in the top 20% of more than the 4,000 stocks that we rank based on trends in earnings estimate revisions and EPS surprises -- the key factors that impact a stock&#39;s near-term price movements.
The Zacks Rank stock-rating system, which uses four factors related to earnings estimates to classify stocks into five groups, ranging from Zacks Rank #1 (Strong Buy) to Zacks Rank #5 (Strong Sell), has an impressive externally-audited track record, with Zacks Rank #1 stocks generating an average annual return of +25% since 1988.
Another factor that confirms the company&#39;s fundamental strength is its Average Broker Recommendation of #1 (Strong Buy). This indicates that the brokerage community is highly optimistic about the stock&#39;s near-term price performance.
So, the price trend in EZPW may not reverse anytime soon.
<a href="https://www.zacks.com/stock/news/2332608/recent-price-trend-in-ezcorp-ezpw-is-your-friend-here-s-why?cid=CS-BENZ-FT-tale_of_the_tape|recent_price_strength_screen-2332608">To read this article on Zacks.com click here.</a>

Trading Ideas

Recent Price Trend in Ezcorp is Your Friend, Here's Why

U.S. stock markets suffered a bloody blow in the first week of August. Wall Street&#39;s turmoil was triggered by weak labor market data, which heightened concerns of a near-term recession. The massive unwinding of Yen-carry trade due to an unexpected rate hike by the Bank of Japan aggravated the situation.
However, U.S. stock markets recovered their lost ground to a great extent within the next 3-4 trading sessions as more released data showed that the fundamentals of the U.S. economy remain firm. Market participants started to buy on the dip.
Consequently, a few stocks have shown price strength. We have primarily targeted stocks that have recently been on a bull run. Such stocks have a high chance of carrying the momentum forward.
If a stock is continuously witnessing an uptrend, there must be a solid reason or it would have probably crashed. So, looking at stocks capable of beating the benchmark that they have set for themselves seems rational.
However, recent price strength alone cannot create magic. Therefore, other relevant parameters are needed to create a successful investment strategy.
Here&#39;s how you should create the screen to shortlist the current as well as the potential winners.
<h2>Screening Parameters:</h2>
Percentage Change in Price (4 Weeks) greater than zero: This criterion shows that the stock has moved higher in the last four weeks.
Percentage Change Price (12 Weeks) greater than 10: This indicates that the stock has seen momentum over the last three months. This lowers the risk of choosing stocks that may have drawn attention due to the overwhelming performance of the overall market in a very short period.
Zacks Rank 1: No matter whether market conditions are good or bad, stocks with a Zacks Rank #1 (Strong Buy) have a proven history of outperformance.
Average Broker Rating 1: This indicates that brokers are also highly hopeful about the stock&#39;s future performance.
Current Price greater than 5: The stocks must all be trading at a minimum of $5.
Current Price/ 52-Week High-Low Range more than 85%: This criterion filters stocks that are trading near their respective 52-week highs. It indicates that these are strong enough in terms of price.
Just these few criteria narrowed down the search from over 7,700 stocks to seven.
Let&#39;s discuss five out of these seven stocks:
Climb Global Solutions Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/clmb#NASDAQ">CLMB</a>) operates as a value-added information technology distribution and solutions company in the United States, Canada, Europe, the United Kingdom, and internationally. CLMB operates in two segments, Distribution and Solutions. CLMB markets its products through its own web sites, local and on-line seminars, events, webinars, and social media, as well as direct email and printed materials.
CLMB distributes technical software to corporate and value-added resellers, consultants, and systems integrators under the name Climb Channel Solutions, and provides cloud solutions and resells software, hardware, and services under the name Grey Matter.
The stock price of Climb Global Solutions has soared 55.2% in the past four weeks. The company has expected earnings growth of 7.4% for the current year. The Zacks Consensus Estimate for the current year has improved 0.001% over the last 60 days.
EZCORP Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ezpw#NASDAQ">EZPW</a>) is engaged in establishing, acquiring, and operating pawnshops that function as convenient sources of consumer credit and value-oriented specialty retailers of primarily previously owned merchandise. Through its lending function, EZPW makes relatively small, non-recourse loans secured by pledges of tangible personal property. EZPW contracts for a pawn service charge to compensate it for each pawn loan.
The stock price of EZCORP has climbed 15.3% in the past four weeks. It has an expected earnings growth rate of 22.8% for the current year (ending September 2024). The Zacks Consensus Estimate for current-year earnings has improved 0.2% over the last 30 days.
Willdan Group Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/wldn#NASDAQ">WLDN</a>) is a provider of professional technical and consulting services to utilities, private industry and public agencies at all levels of government. WLDN enables its clients to realize cost and energy savings by providing a wide range of specialized services.&nbsp;
WLDN assists its clients with a broad range of complementary services relating to: Energy Efficiency and Sustainability, Engineering and Planning, Economic and Financial Consulting, and National Preparedness and Interoperability.
The stock price of Willdan Group has surged 12.1% in the past four weeks. It has an expected earnings growth rate of 12.6% for the current year. The Zacks Consensus Estimate for current-year earnings has improved 5.9% over the last 30 days.
Northwest Pipe Co. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nwpx#NASDAQ">NWPX</a>) manufactures welded steel pipe in two business segments. In Water Transmission business, NWPX is a supplier of large diameter, high-pressure steel pipe used primarily for water transmission. In Tubular Products business, NWPX manufacture smaller diameter, electric resistance welded steel pipe for use in a wide range of construction, agricultural, energy and industrial applications.
The stock price of Northwest Pipe has appreciated 10.4% in the past four weeks. It has an expected earnings growth rate of 41.6% for the current year. The Zacks Consensus Estimate for current-year earnings has improved 20.3% over the last 30 days.
Interface Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tile#NASDAQ">TILE</a>) designs, produces, and sells modular carpet products primarily worldwide. TILE operates in two segments, Americas, and Europe, Africa, Asia and Australia. TILE offers modular carpets under the Interface and FLOR brand names, luxury vinyl tiles, carpet tiles under the CQuestGB name for use in commercial interiors, include offices, healthcare facilities, airports, educational and other institutions, hospitality spaces, and retail facilities, as well as residential interiors; and modular resilient flooring products.&nbsp;
TILE also provides carpet replacement, installation, and maintenance services; and rubber flooring under the norament and noraplan brand names, as well as produces and sells an adapted version of its carpet tile for the healthcare facilities market.
The stock price of Interface has advanced 10.1% in the past four weeks. It has an expected earnings growth rate of 28% for the current year. The Zacks Consensus Estimate for current-year earnings has improved 8.5% over the last 30 days.
Disclosure: Officers, directors and/or employees of Zacks Investment Research may own or have sold short securities and/or hold long and/or short positions in options that are mentioned in this material. An affiliated investment advisory firm may own or have sold short securities and/or hold long and/or short positions in options that are mentioned in this material.
<a href="https://www.zacks.com/stock/news/2322398/5-stocks-with-recent-price-strength-in-an-uncertain-market?cid=CS-BENZ-FT-analyst_blog|rw-2322398">To read this article on Zacks.com click here.</a>

Latin America

Tech

CLMB

NWPX

TILE

WLDN

5 Stocks With Recent Price Strength in an Uncertain Market

U.S. stocks were lower, with the Dow Jones index falling over 900 points on Friday.
Shares of MercadoLibre, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MELI#NASDAQ">MELI</a>) rose sharply during Friday's session after the company reported better-than-expected quarterly financial results.
Mercado Libre reported net revenue of $5.07 billion in the second quarter, up 42% year-over-year. The revenue beat a Street consensus estimate of $4.68 billion, according to data from Benzinga Pro.
The company reported a 36% year-over-year increase in total payment volume for the second quarter and a 20% year-over-year rise in gross merchandise volume. Earnings per share were $10.48 in the second quarter, beating a Street consensus estimate of $8.43.
MercadoLibre shares jumped 9.6% to $1,760.79 on Friday.
Here are some other big stocks recording gains in today's session.
<ul>
<li>Fitell Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTEL#NASDAQ">FTEL</a>) gained 26% to $24.50.</li>
<li>Tandem Diabetes Care, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNDM#NASDAQ">TNDM</a>) shares surged 23.6% to $43.52 in pre-market trading following better-than-expected second-quarter earnings and strong guidance.</li>
<li>Cerus Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CERS#NASDAQ">CERS</a>) gained 23% to $2.5200  after the company reported better-than-expected second-quarter EPS results and raised its FY24 product revenue guidance above estimates..</li>
<li>Integral Ad Science Holding Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IAS#NASDAQ">IAS</a>) shares gained 14.9% to $11.38 after the company reported better-than-expected quarterly financial results and issued FY24 revenue guidance above estimates.</li>
<li>Willdan Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WLDN#NASDAQ">WLDN</a>) climbed 10.1% to $36.52 after the company reported better-than-expected second-quarter financial results.</li>
<li>Fresh Del Monte Produce Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FDP#NYSE">FDP</a>) gained 8.6% to $26.73 following better-than-expected earnings.</li>
<li>ICF International, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICFI#NASDAQ">ICFI</a>) rose 8.3% to $158.06 following upbeat quarterly results.</li>
<li>EZCORP, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EZPW#NASDAQ">EZPW</a>) jumped 8.2% to $11.35.</li>
<li>Standard BioTools Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LAB#NYSE">LAB</a>) gained 7.7% to $1.530.</li>
<li>Bright Horizons Family Solutions Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BFAM#NYSE">BFAM</a>) gained 7.5% to $127.32 following strong quarterly results.</li>
<li>DoorDash, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DASH#NASDAQ">DASH</a>) rose 6.7% to $115.52 as the company posted upbeat earnings.</li>
<li>GoDaddy Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GDDY#NYSE">GDDY</a>) jumped 5.8% to $149.66 after the company reported better-than-expected second-quarter sales results..</li>
<li>The Clorox Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLX#NYSE">CLX</a>) gained 4.3% to $139.94 after the company reported better-than-expected fourth-quarter adjusted EPS results and issued FY24 adjusted EPS guidance above estimates.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/08/40131885/dow-dips-over-400-points-apple-posts-upbeat-earnings">Dow Dips Over 400 Points; Apple Posts Upbeat Earnings</a></li>
</ul>

Intraday Update

Movers

BFAM

CERS

DASH

FTEL

GDDY

ICFI

MELI

TNDM

MercadoLibre Posts Upbeat Results, Joins Integral Ad Science, Willdan Group, Fresh Del Monte Produce And Other Big Stocks Moving Higher On Friday

EZCORP (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EZPW#NASDAQ">EZPW</a>) reported quarterly earnings of $0.23 per share which beat the analyst consensus estimate of $0.21 by 9.52 percent. The company reported quarterly sales of $281.421 million which beat the analyst consensus estimate of $279.546 million by 0.67 percent. This is a 10.01 percent increase over sales of $255.812 million the same period last year.

EZCORP Q3 2024 Adj. EPS $0.23 Beats $0.21 Estimate, Sales $281.421M Beat $279.546M Estimate

U.S. stock futures were higher this morning, with the Dow futures gaining around 150 points on Monday.
Shares of Abbott Laboratories (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>) fell in today&#8217;s pre-market trading after the company was ordered to pay $495 million in damages in its baby formula case.
Abbott shares lost 6.6% to $98.29 in pre-market trading
<ul>
<li>Integra LifeSciences Holdings Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IART#NASDAQ">IART</a>) dipped 20.5% to $25.00 in pre-market trading after the company reported second-quarter results and lowered its FY24 outlook.</li>
<li>NewAmsterdam Pharma Company N.V. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NAMS#NASDAQ">NAMS</a>) fell 13.8% to $16.26 in pre-market trading as the company announced topline data from pivotal Phase 3 BROOKLYN clinical trial evaluating Obicetrapib in patients wth Heterozygous Familial Hypercholesterolemia.</li>
<li>EZCORP, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EZPW#NASDAQ">EZPW</a>) shares declined 8.8% to $9.41 in pre-market trading.</li>
<li>GeoPark Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GPRK#NYSE">GPRK</a>) shares fell 6.5% to $9.52 in pre-market trading. GeoPark, last week, issued second quarter operational update.</li>
<li>Immutep Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMMP#NASDAQ">IMMP</a>) shares dipped 6.5% to $2.03 in pre-market trading. Immutep, last week, announced successful meeting with the FDA on Phase III design in non-small cell lung cancer.</li>
<li>Iovance Biotherapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IOVA#NASDAQ">IOVA</a>) shares fell 5.4% to $8.75 in pre-market trading.</li>
<li>ICL Group Ltd (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ICL#NYSE">ICL</a>) shares fell 4.1% to $4.43 in pre-market trading. ICL will release second quarter results before the opening of the TASE market on Wednesday, Aug. 14.</li>
<li>PDD Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PDD#NASDAQ">PDD</a>) slipped 3% to $126.84 in pre-market trading.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/07/39984123/jim-cramer-is-mystified-by-five-below-predicts-crowdstrike-is-going-to-bottom-here">Jim Cramer Is &#8216;Mystified&#8217; By Five Below, Predicts CrowdStrike &#8216;Is Going To Bottom Here&#8217;</a></li>
</ul>

Pre-Market Outlook

GPRK

IART

IMMP

IOVA

NAMS

Citigourp Global Markets 2% Protected Notes Linked To The Djia

Abbott, Integra LifeSciences And Other Big Stocks Moving Lower In Monday's Pre-Market Session

Comments

EZCORP

空売り

EZCORP (NASDAQ:EZPW) 株価情報, 空売り情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル